학술논문
192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
Document Type
Abstract
Author
Source
In ESMO Open May 2023 8(1) Supplement 4
Subject
Language
ISSN
2059-7029